Wegovy Maker Novo Nordisk Stock Surges on Promising Trial of Obesity Pill Amycretin

KEY TAKEAWAYSNovo Nordisk's experimental weight loss treatment amcryetin reportedly shows promising results in a Phase I trial.Early results suggest that it may be more effective than the highly popular Wegovy.The Phase II trial of the drug will be launched in the second half of 2024, with results expected in early 2026.Novo Nordisk's shares jumped to a new record high and were up more than 8% in early trading Thursday in New York. The American depositary receipts (ADRs) of Novo Nordisk A/S (NVO) gained mor ...